Evidence map›Paper›PMID 38470651›Full record

ArticleHealthcare (Basel, Switzerland)2024

Vision-Related Quality of Life in Patients with Systemic Lupus Erythematosus.

Francisco de Asís Bartol-Puyal, María Chacón González, Borja Arias-Peso, Damián García Navarro, Silvia Méndez-Martínez, María Pilar Ruiz Del Tiempo, Luis Sáez Comet, Luis Pablo Júlvez

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francisco de Asís Bartol-PuyalOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-4476-6003
María Chacón GonzálezOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Borja Arias-PesoOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Damián García NavarroOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Silvia Méndez-MartínezOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
María Pilar Ruiz Del TiempoOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Luis Sáez CometInternal Medicine Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-9868-6498
Luis Pablo JúlvezOphthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess vision-related quality of life (VRQoL) in patients with systemic lupus erythematosus (SLE) under treatment with hydroxychloroquine (HCQ), and to find the influencing factors.

methodsCross-sectional study enrolling SLE patients for less than ten years (Group 1), SLE patients for more than ten years (Group 2), and healthy controls (Group 3). SLE patients should be under treatment with HCQ but without ophthalmological affection. Schirmer test, best-corrected visual acuity (BCVA), axial length (AL) with optical biometry, and swept-source optical coherence tomography-angiography (OCTA) Triton (Topcon) were performed. All participants fulfilled the Impact of Visual Impairment questionnaire, and SLE patients answered the Lupus Impact Tracker (LIT) questionnaire. Additional data were obtained from clinical records.

resultsA totals of 41 eyes (41 patients), 31 eyes (31 patients) and 45 eyes (45 volunteers) were enrolled in the study groups. The mean ages were 41.09 ± 9.56, 45.06 ± 8.47 and 40.25 ± 10.83 years, respectively (

conclusionsDespite no ophthalmological affection, SLE patients refer to poorer VRQoL because of disease activity and a low health-related quality of life, which has a negative influence on VRQoL. This masks the effect of other ophthalmological conditions such as dry eyes. Other variables influencing VRQoL are age and BMI, and BCVA, to a lesser extent.

Indexed as

hydroxychloroquineimpact of visual impairment questionnairesystemic lupus erythematosusvision-related quality of life

Identifiers

PMID38470651
PMCPMC10931292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.